NNC0194-0499 and Semaglutide Combination Explored for Type 1 Diabetes Blood Sugar Control

Managing Type 1 Diabetes (T1D) remains a significant challenge, primarily due to the autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Despite advancements in insulin therapy, many individuals struggle to achieve optimal glycemic control, facing risks of both hypoglycemia and hyperglycemia, and long-term complications affecting cardiovascular, renal, and neurological systems. Current standard of care relies solely on exogenous insulin, which often falls short in fully replicating physiological glucose regulation. There's a critical need for adjunctive therapies that can stabilize blood glucose, reduce insulin requirements, and improve overall metabolic health. GLP-1 receptor agonists, like semaglutide, have demonstrated significant benefits in Type 2 Diabetes (T2D), including improved glycemic control, weight loss, and cardiovascular protection, by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. This study investigates a novel compound, NNC0194-0499, alone and in combination with semaglutide, to explore its potential as an adjunctive treatment for T1D.

This is a randomized, quadruple-blinded, placebo-controlled Phase 1 clinical trial designed to investigate the efficacy and safety of NNC0194-0499 alone or in combination with semaglutide in people with Type 1 Diabetes. An estimated 96 participants will be enrolled. The study design includes several intervention arms: participants will receive NNC0194-0499 via subcutaneous once weekly injection, or semaglutide via subcutaneous once weekly injection, or a combination of both, or matched placebo. The primary endpoints of this early-phase study are focused on assessing the safety and tolerability profile of NNC0194-0499, both as monotherapy and in combination, including the incidence and severity of adverse events. Secondary endpoints will evaluate preliminary signals of efficacy related to blood sugar control, such as changes in HbA1c, fasting plasma glucose, time in range, and insulin dose requirements.

As an ongoing Phase 1 trial, specific efficacy or safety findings are not yet available, with the study scheduled to commence in July 2025. However, the trial is designed to establish the initial safety and tolerability profile of NNC0194-0499 alone and in combination with semaglutide in individuals with Type 1 Diabetes. Key anticipated outcomes will include the comprehensive assessment of adverse events, their frequency, and severity, which are crucial for determining the compound's safety for further development. Preliminary efficacy signals will also be explored through changes in various glycemic parameters. These include monitoring for improvements in HbA1c levels, reductions in fasting plasma glucose, and an increase in time in range (the percentage of time blood glucose levels are within a target range). Additionally, the study will investigate any potential impact on daily insulin dose requirements, which could indicate an insulin-sparing effect. The trial aims to identify optimal dosing strategies for NNC0194-0499 and assess any synergistic or additive effects when combined with semaglutide on overall glucose homeostasis. Future publications will detail these initial safety and preliminary efficacy signals, which are essential for advancing NNC0194-0499 into later development phases and potentially offering a new therapeutic option for T1D patients.